Caribou Biosciences Raises $125M Via Equity Just One Week After Pfizer Invested $25M
Portfolio Pulse from Vandana Singh
Caribou Biosciences has raised $125 million through an upsized underwritten public offering of 19.2 million shares at $6.50 per share. This comes a week after Pfizer invested $25 million in the company. Caribou also reported long-term follow-up data from the dose escalation portion of the ongoing ANTLER Phase 1 trial of CB-010, an allogeneic anti-CD19 CAR-T cell therapy for relapsed or refractory B cell non-Hodgkin lymphoma.
July 14, 2023 | 1:28 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Pfizer recently invested $25 million in Caribou Biosciences. The investment is intended to advance CB-011 development.
Pfizer's investment in Caribou Biosciences is significant, but it's unclear how this news will impact Pfizer's stock in the short term.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 50
NEGATIVE IMPACT
Caribou Biosciences has raised significant capital through equity and has reported positive data from its ongoing trial. However, its shares are down 15.60% in premarket trading.
The capital raised and positive trial data are significant for Caribou Biosciences. However, the drop in share price indicates a negative short-term impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100